Q2 Earnings Forecast for Oculis Issued By Leerink Partnrs

Oculis Holding AG (NASDAQ:OCS - Free Report) - Investment analysts at Leerink Partnrs dropped their Q2 2025 EPS estimates for shares of Oculis in a research note issued to investors on Wednesday, June 4th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.50) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for Oculis' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.51) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($3.49) EPS, FY2028 earnings at ($2.20) EPS and FY2029 earnings at $0.43 EPS.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. The firm had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million.

OCS has been the subject of several other research reports. HC Wainwright increased their target price on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, April 17th. Robert W. Baird lifted their price objective on shares of Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th. Finally, Chardan Capital upped their target price on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research report on Friday, May 9th.

Oculis Price Performance

OCS stock traded up $0.05 during trading on Monday, reaching $19.68. The company's stock had a trading volume of 19,651 shares, compared to its average volume of 44,726. The company's fifty day moving average is $18.07 and its 200-day moving average is $18.81. Oculis has a 1 year low of $10.79 and a 1 year high of $23.08. The company has a market capitalization of $859.27 million, a P/E ratio of -10.20 and a beta of 0.35. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01.

Institutional Trading of Oculis

Large investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares during the last quarter. Bellevue Group AG purchased a new position in Oculis during the 4th quarter valued at $170,000. Bank of America Corp DE lifted its position in shares of Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after purchasing an additional 10,667 shares during the last quarter. Kestra Private Wealth Services LLC purchased a new position in Oculis in the 1st quarter worth about $234,000. Finally, XTX Topco Ltd bought a new position in Oculis in the 4th quarter worth about $225,000. Institutional investors own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.